Science Journal Retracts Paper That Sparked CRISPR PanicGizmodoLast May, a journal published results suggesting that the revolutionary gene-editing technique CRISPR might actually be quite dangerous. The paper caused a bit of turmoil in the biotech wor… Continue reading
OncLiveDr. Bachier Discusses Toxicities With Stem Cell TransplantOncLiveCarlos R. Bachier, MD, director, blood and marrow transplant research, Sarah Cannon Research Institute, discusses toxicities associated with stem cell transplant. Stem cell transpl… Continue reading
Dr. Balmanoukian on Clinical Trials With Immunotherapy in GU CancersOncLiveAni S. Balmanoukian, MD, director of Thoracic Oncology, and associate director of the Phase I Immune-Oncology Program at The Angeles Clinic and Research Institute, discusses the… Continue reading
CBS New YorkStem Cell Researcher FiredGenomeWebKyoto University has fired an investigator for falsifying figures in a 2017 Stem Cell Reports paper, Retraction Watch reports. It adds that Nobel Laureate Shinya Yamanaka, who directs the Center for iPS Ce… Continue reading
Immunotherapy Calls Up Natural Killer Cells in the Fight against CancerGenetic Engineering & Biotechnology NewsCancer immunotherapy frequently goads T cells to fight cancer more zealously, and now it is starting to demand more of natural killer (NK) ce… Continue reading
|
Solid Recommits to DMD Gene Therapy on Clinical Hold, as Stock Plunge Sparks Lawsuits
Genetic Engineering & Biotechnology News Solid Biosciences restated its commitment to developing its lead candidate, the Duchenne muscular dystrophy (DMD) gene therapy SGT-001, despite the FDA’s full and partial clinical holds on a Phase I/II trial for the treatment. The FDA last month … |
|
Solid Recommits to DMD Gene Therapy on Clinical Hold, as Stock Plunge Sparks Lawsuits
Genetic Engineering & Biotechnology News Solid Biosciences restated its commitment to developing its lead candidate, the Duchenne muscular dystrophy (DMD) gene therapy SGT-001, despite the FDA’s full and partial clinical holds on a Phase I/II trial for the treatment. The FDA last month … |
|
Solid Recommits to DMD Gene Therapy on Clinical Hold, as Stock Plunge Sparks Lawsuits
Genetic Engineering & Biotechnology News Solid Biosciences restated its commitment to developing its lead candidate, the Duchenne muscular dystrophy (DMD) gene therapy SGT-001, despite the FDA’s full and partial clinical holds on a Phase I/II trial for the treatment. The FDA last month … |